Europe — EMA

Nuvaxovid

Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M, the active ingredient in Nuvaxovid, is a vaccine presented as a unknown/unknown for unknown use.

Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M

Request sourcing

Pack/s

What is Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M?

Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M, the active ingredient in Nuvaxovid, is a vaccine presented as a unknown/unknown for unknown use. It treats COVID‑19 by prevent prevent ... .

GNH USA supplies Nuvaxovid as a licensed ... .

What is Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M used for?

Nuvaxprevent g

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →

Product details

Drug

Sars-Cov-2, Spike Protein, Recombinant, Expressed In Sf9 Cells Derived From Spodoptera Frugiperda, M

Route

Intramuscular Use

Manufacturer

Novavax Cz A.S.

Origin